From GlobeNewswire: 2025-04-23 03:30:00

Pharming Group N.V. announces that Joenja®, the first medicine for APDS, has been recommended for reimbursement and use within the NHS in England and Wales. The NICE recommendation is based on positive Phase III trial results showing significant improvements in immune deficiency and dysregulation with leniolisib treatment. This marks a significant milestone for patients with APDS, a rare primary immunodeficiency. Leniolisib is now available for use in England through the Innovative Medicines Fund and will soon be funded in Wales through the NHS. This targeted therapy addresses the fundamental cause of immune system problems in APDS, providing real benefits for patients.



Read more at GlobeNewswire: Pharming receives positive recommendation from NICE for